This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Today's Small-Cap Winners and Losers

Spherix (SPEX) surged 54% after the company said an agreement for a multinational late-stage clinical trial of its Naturlose as a type 2 diabetes drug is being completed.

Preliminary work is under way, and patient recruitment is expected to begin before the end of the year. Spherix has a unit that provides contact center information and reservations services and another involved in product development in the health, medicine and environmental fields. Shares of Spherix were up $1.12 to $3.20.

Scolr Pharma (DDD) was dropping after the company released its financial results for fiscal 2005. Scolr lost $8.9 million, or 26 cents a share, last year, compared with a restated loss of $5.7 million and 19 cents a share for fiscal 2004.

Royalties from its dietary supplement products for 2005 totaled $635,407, an increase of 44% from the previous year. Shares of Scolr were losing 62 cents, or 9.8%, to $5.68.

RightNow Technologies (RNOW) jumped after the software company was upgraded by First Albany to strong buy from buy. Separately, the company announced that it had signed its 100th higher-education customer, Australia's Edith Cowan University. Shares gained $1.69, or 11.3%, to $16.62.

ICT Group (ICTG) stumbled after the customer-management software concern said it filed regulatory documents for a proposed public offering of 3 million shares.

The company said it will sell 2 million shares and stockholders will sell 1 million shares. Underwriters have the option to buy an additional 440,000 shares to cover overallotments. Shares of ICT were sinking $3.10, or 11.6%, to $23.60.

Harmonic (HLIT) caught a bid following word that the digital-video systems company was upgraded by Kaufman Bros. to buy from hold. Shares gained 45 cents, or 7.5%, to $6.44. ChemGenex Pharmaceuticals (CXSP) was climbing after the company announced the publication of preclinical research supporting the expansion of its development of Ceflatonin to include the treatment of acute myeloid leukemia patients in addition to those with chronic myeloid leukemia and myelodysplastic syndrome.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs